Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Medical Information FSGS

FILSPARI (sparsentan): Changes in Blood Pressure and Hypotensive Events in FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Learn more
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More
Abstracts IgAN

Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

View
Abstracts IgAN

Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

View
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View